ImmunityBio Gets FDA Expanded Access for ANKTIVA in Solid Tumors
ImmunityBio, Inc. announced that the U.S. Food and Drug Administration (FDA) has granted Expanded Access authorization for the use of its Cancer BioShield platform, anchored by ANKTIVA®…
Read More...
Read More...
